546 related articles for article (PubMed ID: 17187694)
1. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
2. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
3. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
4. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
5. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Mostafid AH; Rajkumar RG; Stewart AB; Singh R
BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
7. [Bladder necrosis after an immediate post-operative mitomycin C instillation].
Branchereau J; Luyckx F; Hitier M; Karam G; Bouchot O; Rigaud J
Prog Urol; 2011 Feb; 21(2):151-3. PubMed ID: 21296285
[TBL] [Abstract][Full Text] [Related]
8. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
9. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
10. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
Okumura A; Oishi N; Kaji K; Imamura T; Fuse H
J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691
[TBL] [Abstract][Full Text] [Related]
11. Histological changes due to intravesical instillation of mitomycin C.
Castillo OA; Landerer E; Feria-Flores M; Vidal-Mora I; Franco C
Arch Esp Urol; 2012 Jun; 65(5):578-82; discussion 582. PubMed ID: 22732786
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
[TBL] [Abstract][Full Text] [Related]
13. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H
BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
[TBL] [Abstract][Full Text] [Related]
14. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
[TBL] [Abstract][Full Text] [Related]
15. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!
Fazlioglu A; Tandogdu Z; Kurtulus FO; Parlakkilic O; Cek M
Urol Int; 2009; 83(3):362-3. PubMed ID: 19829042
[TBL] [Abstract][Full Text] [Related]
16. [Early postoperative mitomycin C instillation: when and how?].
Traxer O; Gattegno B
Prog Urol; 2004 Apr; 14(2):249-51. PubMed ID: 15217151
[TBL] [Abstract][Full Text] [Related]
17. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
Rouprêt M; Guillotreau J; Irani J; Zerbib M
Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
19. Intravesical mitomycin-C-induced interstitial pneumonia.
Wada H; Nakano Y; Yamada H; Saiga T; Yamanaka A; Sakai N
Respiration; 2010; 80(3):256-9. PubMed ID: 20130385
[TBL] [Abstract][Full Text] [Related]
20. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Irani J
Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
